Valuation: Savara Inc.

Market Cap 1.48B 1.28B 1.2B 1.09B 2.06B 141B 2.09B 14.03B 5.5B 70.54B 5.55B 5.43B 235B P/E 2026 *
-10.9x
P/E 2027 * -19.7x
Enterprise Value 1.48B 1.28B 1.2B 1.09B 2.06B 141B 2.09B 14.03B 5.5B 70.54B 5.55B 5.43B 235B EV / Sales 2026 *
579x
EV / Sales 2027 * 17.7x
Free-Float
92.35%
Yield 2026 *
-
Yield 2027 * -
06-23 Savara Insider Sold Shares Worth $2,241,432, According to a Recent SEC Filing MT
06-08 Savara Inc. Announces CFO Changes CI
06-08 Savara Inc. Announces Step Down of Dave Lowrance as Chief Administrative Officer, Effective July 15, 2026 CI
05-18 Savara Inc Announces New Exercise Capacity Data From The IMPALA-2 Phase 3 Clinical Trial Of Molgramostim Inhalation Solution In Autoimmune Pulmonary Alveolar Proteinosis CI
05-12 Savara Q1 Loss Widens MT
05-12 Earnings Flash (SVRA) Savara Posts Q1 Per Share Loss $-0.15, vs. FactSet Est of $-0.13 Loss MT
05-12 Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-24 Oppenheimer Adjusts Price Target on Savara to $11 From $9, Maintains Outperform Rating MT
04-15 Savara announces the U.S. Food & Drug Administration (FDA) has extended the review period for the molgramostim inhalation solution (molgramostim) biologics license application (BLA) in autoimmune pulmonary alveolar proteinosis (autoimmune PAP) RE
04-15 Savara Says FDA Extended Review Period for Molgramostim Inhalation Solution Application MT
04-15 Savara Announces the U.S. Food & Drug Administration Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application in Autoimmune Pulmonary Alveolar Proteinosis CI
04-07 Savara Inc. Announces MHRA Accepts Molbreevi Marketing Authorisation Application for Autoimmune PAP CI
04-07 Savara Says UK Health Care Body Accepts Submission of Marketing Authorization Application for Molbreevi MT
1 day-1.11%
1 week+8.07%
Current month+5.49%
1 month-4.48%
3 months+12.50%
6 months+9.30%
Current year-4.48%
1 week 5.36
Extreme 5.36
5.99
1 month 5.18
Extreme 5.18
6.02
Current year 4.7
Extreme 4.695
6.49
1 year 2.43
Extreme 2.43
7
3 years 1.89
Extreme 1.89
7
5 years 1.02
Extreme 1.02
7
10 years 0.69
Extreme 0.69
17.19
Manager TitleAgeSince
Chief Executive Officer 56 30/11/2020
Director of Finance/CFO 57 14/07/2026
Chief Tech/Sci/R&D Officer 56 30/11/2023
Director TitleAgeSince
Director/Board Member 58 31/01/2009
Director/Board Member 77 30/09/2010
Director/Board Member 72 30/09/2013
Date Insider Type Main position Quantity % Market Cap.
15/07/26 Free

Chief Financial Officer

105,000 0.0512%
16/02/26 Fiscal year

Director

3,614 0.0018%
19/12/25 Sell

Director

20,000 0.0098%
Change 5-day change 1-year change 3-year change Capi.($)
-1.97%+8.07%+113.33%+50.00% 1.48B
+4.21%+25.62%+77.96%+111.62% 68.12B
+0.50%+6.20%+38.65%+67.83% 55.18B
+1.82%+35.25%+17.95%+486.05% 28.63B
+0.57%+19.05%+57.08%+5.18% 23.99B
-0.44%+1.08%-14.65%-11.58% 23.53B
-0.35%+7.91%+46.74%-22.61% 18.45B
-2.04%+9.24%+31.14%+650.71% 16.44B
+7.26%+25.47%+221.03%+383.67% 15.83B
-2.27%-4.40%+40.70%+148.87% 13.4B
Average +0.77%+10.86%+62.99%+186.97% 26.5B
Weighted average by Cap. +1.53%+11.61%+54.96%+164.25%

Financials

2026 *2027 *
Net sales 2.55M 2.21M 2.06M 1.89M 3.56M 243M 3.61M 24.21M 9.5M 122M 9.58M 9.37M 405M 83.42M 72.22M 67.5M 61.69M 116M 7.96B 118M 792M 311M 3.98B 313M 306M 13.26B
Net income -137M -119M -111M -101M -191M -13.07B -194M -1.3B -510M -6.54B -514M -503M -21.77B -61.66M -53.38M -49.89M -45.6M -85.92M -5.88B -87.27M -585M -230M -2.94B -232M -226M -9.8B
Net Debt - -
Logo Savara Inc.
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Employees
70
Date Price Change Volume
10/08/26 US$5.735 -1.63% 364,715
07/08/26 US$5.830 +0.69% 1,586,205
06/08/26 US$5.790 +5.08% 1,007,710
05/08/26 US$5.510 +1.85% 1,602,632
04/08/26 US$5.410 +1.50% 1,361,577
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
5.830USD
Average target price
10.94USD
Spread / Average Target
+87.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SVRA Stock